ARTA
RGLS

A.R.T. Advisors’s Regulus Therapeutics RGLS Stock Holding History

A.R.T. Advisors’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,180
Closed -$8K – 226
2020
Q2 		$8K Buy
+1,180
New +$7.72K 0.01% 279
2019
Q3 		– Sell
-1,610
Closed -$20K – 1683
2019
Q2 		$20K Buy
1,610
+508
+46% +$5.85K ﹤0.01% 1296
2019
Q1 		$11K Buy
+1,102
New +$12K ﹤0.01% 1256
2018
Q3 		– Sell
-304
Closed -$24K – 1650
2018
Q2 		$24K Sell
304
-1,108
-78% -$91.7K ﹤0.01% 1356
2018
Q1 		$121K Buy
+1,412
New +$189K ﹤0.01% 1338
2017
Q4 		– Sell
-207
Closed -$31K – 1615
2017
Q3 		$31K Sell
207
-1,955
-90% -$246K ﹤0.01% 1279
2017
Q2 		$255K Sell
2,162
-143
-6% -$23.9K 0.01% 1072
2017
Q1 		$456K Buy
2,305
+1,552
+206% +$295K 0.02% 846
2016
Q4 		$203K Buy
753
+604
+405% +$196K 0.01% 1060
2016
Q3 		$59K Buy
+149
New +$61.3K 0.02% 588
2015
Q2 		– Sell
-505
Closed -$1.02M – 1674
2015
Q1 		$1.02M Buy
+505
New +$1.1M 0.04% 646

Other funds holding RGLS

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

A.R.T. Advisors's RGLS Position: Q3 2020 in Review

A.R.T. Advisors sold out of Regulus Therapeutics (RGLS) in Q3 2020, closing a stake of 1,180 shares — an estimated $8K sold.

A.R.T. Advisors first reported a position in RGLS in Q1 2015 and held it in 11 quarters. The position peaked at $1.02M in Q1 2015. 27 funds tracked by Wall St. Rank hold RGLS as of Q3 2020.

  • A.R.T. Advisors reported no remaining Regulus Therapeutics position as of Q3 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 1,180 Regulus Therapeutics shares in Q3 2020, an estimated $8K.
  • A.R.T. Advisors first reported a position in Regulus Therapeutics in Q1 2015 and held it in 11 quarters.
  • A.R.T. Advisors's Regulus Therapeutics position peaked at $1.02M in Q1 2015.
  • 27 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q3 2020.

Based on A.R.T. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.